Genetic association of five plasminogen activator inhibitor-1 (PAI-1) polymorphisms and idiopathic recurrent pregnancy loss in Korean women

Thrombosis and Haemostasis

Volumn 110, Issue 4, 2013, Pages 742-750

  Jeon, Young Joo ^a   Kim, Young Ran ^a   Lee, Bo Eun ^a   Choi, Yi Seul ^a   Kim, Ji Hyang ^a   Shin, Ji Eun ^a   Rah, HyungChul ^a   Cha, Sun Hee ^a   Lee, Woo Sik ^a   Kim, Nam Keun ^a  

^a CHA University   (South Korea)

Author keywords

Plasminogen activator inhibitor 1; Polymorphism; Recurrent pregnancy loss

Indexed keywords

CHOLESTEROL; FOLIC ACID; HOMOCYSTEINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; URATE;

ABORTION; ADULT; ARTICLE; COLORIMETRY; CONTROLLED STUDY; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPING TECHNIQUE; HAPLOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTHROMBIN TIME; RECURRENT ABORTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

PLASMINOGEN ACTIVATOR INHIBITOR-1; POLYMORPHISM; RECURRENT PREGNANCY LOSS;

ABORTION, HABITUAL; ADULT; BLOOD COAGULATION; DNA MUTATIONAL ANALYSIS; FEMALE; FOLIC ACID; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTEINE; HUMANS; KOREA; MIDDLE AGED; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PREGNANCY; YOUNG ADULT;

EID: 84884832503     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-03-0242     Document Type: Article

References (47)

1. Stephenson M, Kutteh W. Evaluation and management of recurrent early pregnancy loss. Clin Obstet Gynecol 2007; 50: 132-145.
2. Coulam CB, Clark DA, Beer AE, et al. Current clinical options for diagnosis and treatment of recurrent spontaneous abortion. Am J Reprod Immunol 1997; 38: 57-74.
3. Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril 2013; 99: 63.
4. Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril 2010; 93: 1234-1243.
5. Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril 2012; 98: 1103-1111.
6. Francis C, Marder V. Mechanisms of fibrinolysis. In: Williams Haematology. 5th ed. McGraw Hill 1995; pp. 1252-1260.
7. Lijnen HR, Collen D. Mechanisms of physiological fibrinolysis. Baillieres Clin Haematol 1995; 8: 277-290.
8. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640.
9. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
10. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation 1999; 99: 2496-2498.
11. Sappino AP, Huarte J, Belin D, et al. Plasminogen activators in tissue remodeling and invasion: mRNA localisation in mouse ovaries and implanting embryos. J Cell Biol 1989; 109: 2471-2479.
12. Piquette GN, Simon C, el Danasouri I, et al. Gene regulation of interleukin-1 beta, interleukin-1 receptor type 1, and plasminogen activator inhibitor-1 and-2 in human granulosa-luteal cells. Fertil Steril 1994; 62: 760-770.
13. Hu ZY, Liu YX, Liu K, et al. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta. J Anat 1999; 194: 183-195.
14. Graham CH. Effect of transforming growth factor-beta on the plasminogen activator system in cultured first trimester human cytotrophoblasts. Placenta 1997; 18: 137-143.
15. Ma Z, Jhun B, Jung SY, et al. Binding of upstream stimulatory factor 1 to the E-box regulates the 4G/5G polymorphism-dependent plasminogen activator inhibitor 1 expression in mast cells. J Allergy Clin Immunol 2008; 121: 1006-1012.
16. Ma Z, Paek D, Oh CK. Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation. Clin Exp Allergy 2009; 39: 1136-1144.
17. Hultman K, Tjarnlund-Wolf A, Odeberg J, et al. Allele-specific transcription of the PAI-1 gene in human astrocytes. Thromb Haemost 2010; 104: 998-1008.
18. Su MT, Lin SH, Chen YC, et al. Genetic association studies of ACE and PAI-1 genes in women with recurrent pregnancy loss. A systematic review and metaanalysis. Thromb Haemost 2013; 109: 8-15.
19. Morange PE, Saut N, Alessi MC, et al. Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol 2007; 27: 2250-2257.
20. Barch MJ, Knutsen T, Spurbeck JL. The AGT Cytogenetics Laboratory Manual. 3rd ed. New York, Lippincott-Raven publishers; 1997.
21. Jeon YJ, Choi YS, Rah HC, et al. The reduced folate carrier-1 (RFC1 696T>C) polymorphism is associated with spontaneously aborted embryos in Koreans. Genes Genom 2011; 33: 223-228.
22. Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69: 138-147.
23. Moore JH, Williams SM. New strategies for identifying gene-gene interactions in hypertension. Ann Med 2002; 34: 88-95.
24. Lee SY, Chung Y, Elston RC, et al. Log-linear model-based multifactor dimensionality reduction method to detect gene gene interactions. Bioinformatics 2007; 23: 2589-2595.
25. Alturfan AA, Eralp L, Emekli N. Investigation of inflammatory and hemostatic parameters in female patients undergoing total knee arthroplasty surgery. Inflammation 2008; 31: 414-421.
26. Su MT, Lin SH, Chen YC. Genetic association studies of angiogenesisand vasoconstriction-related genes in women with recurrent pregnancy loss: a systematic review and meta-analysis. Hum Reprod Update 2011; 17: 803-812.
27. Buchholz T, Thaler CJ. Inherited thrombophilia: impact on human reproduction. Am J Reprod Immunol 2003; 50: 20-32.
28. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-916.
29. Hickey M, Fraser IS. Clinical implications of disturbances of uterine vascular morphology and function. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14: 937-951.
30. Lockwood CJ. Regulation of plasminogen activator inhibitor 1 expression by interaction of epidermal growth factor with progestin during decidualisation of human endometrial stromal cells. Am J Obstet Gynecol 2001; 184: 798-804.
31. Smith AN, Carter QL, Kniss DA, et al. Characterisation of a TGFbeta-responsive human trophoblast-derived cell line. Placenta 2001; 22: 425-431.
32. Chakraborty C, Gleeson LM, McKinnon T, et al. Regulation of human trophoblast migration and invasiveness. Can J Physiol Pharmacol 2002; 80: 116-124.
33. Kappelmayer J, Bacskó G, Kelemen E, et al. Onset and distribution of factor XIII-containing cells in the mesenchyme of chorionic villi during early phase of human placentation. Placenta 1994; 15: 613-623.
34. Anwar R, Gallivan L, Edmonds SD, et al. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood 1999; 93: 897-905.
35. Glueck CJ, Phillips H, Cameron D, et al. The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism 2000; 49: 845-852.
36. Maiello M, Torella M, Caserta L, et al. Hypercoagulability during pregnancy: evidences for a thrombophilic state. Minerva Ginecol 2006; 58: 417-422.
37. Harville EW, Viikari JS, Raitakari OT. Preconception cardiovascular risk factors and pregnancy outcome. Epidemiology 2011; 22: 724-730.
38. Bergen NE, Jaddoe VW, Timmermans S, et al. Homocysteine and folate concentrations in early pregnancy and the risk of adverse pregnancy outcomes: the Generation R Study. Br J Obstet Gynecol 2012; 119: 739-751.
39. Akahori Y, Masuyama H, Hiramatsu Y. The correlation of maternal uric acid concentration with small-for-gestational-age fetuses in normotensive pregnant women. Gynecol Obstet Invest 2012; 73: 162-167.
40. Lyngdoh T, Marques-Vidal P, Paccaud F, et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS One 2011; 6: e19901.
41. Nakashima A, Shima T, Inada K, et al. The balance of the immune system between T cells and NK cells in miscarriage. Am J Reprod Immunol 2012; 67: 304-310.
42. Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 2010; 28: e72-91.
43. Di Minno MN, Tremoli E, Coppola A, et al. Homocysteine and arterial thrombosis: Challenge and opportunity. Thromb Haemost 2010; 103: 942-961.
44. Akpek M, Kaya MG, Uyarel H, et al. The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI. Atherosclerosis 2011; 219: 334-341.
45. Vanizor Kural B, Orem A, Cimşit G, et al. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003; 332: 23-30.
46. Tofler GH, D'Agostino RB, Jacques PF, et al. Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk. Thromb Haemost 2002; 88: 799-804.
47. Wei W, Liu SY, Zeng FF, et al. Meta-analysis of the association of the C677T polymorphism of the methylenetetrahydrofolate reductase gene with hyperuricemia. Ann Nutr Metab 2012; 60: 44-51.